0.60
+0.0362(+6.46%)
Currency In USD
| Previous Close | 0.56 |
| Open | 0.56 |
| Day High | 0.61 |
| Day Low | 0.56 |
| 52-Week High | 3.65 |
| 52-Week Low | 0.25 |
| Volume | 1.08M |
| Average Volume | 5.51M |
| Market Cap | 18.07M |
| PE | -0.16 |
| EPS | -3.74 |
| Moving Average 50 Days | 0.58 |
| Moving Average 200 Days | 1.26 |
| Change | 0.04 |
If you invested $1000 in Moleculin Biotech, Inc. (MBRX) since IPO date, it would be worth $0.83 as of August 21, 2025 at a share price of $0.597. Whereas If you bought $1000 worth of Moleculin Biotech, Inc. (MBRX) shares 5 years ago, it would be worth $7.22 as of August 21, 2025 at a share price of $0.597.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
GlobeNewswire Inc.
Aug 14, 2025 1:15 PM GMT
– Live video webcast on Wednesday, August 20th at 2:00 PM ET HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug cand
Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment
GlobeNewswire Inc.
Aug 06, 2025 12:40 PM GMT
Presented data highlights the potential of Annamycin for treating broad range of human cancers, including high-need oncology indications Annamycin currently in late-stage clinical development in combination with cytarabine for the treatment of AML;
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin
GlobeNewswire Inc.
Jul 30, 2025 12:35 PM GMT
– New patent enhances market position in Europe HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeti